Lilly’s Omvoh now available in the U.S. for ulcerative colitis
The Food and Drug Administration has approved Eli Lilly and Co.’s Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), as the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.